Browse the corpus

Leukemia is a heterogeneous group of hematologic malignancies that arise from the dysfunctional proliferation of developing leukocytes. It is classified as either acute or chronic based on the rapidity of proliferation and as myelocytic or lymphocytic based on the cell of origin. Treatment depends on the type of leukemia but generally involves chemotherapy. Multiple genetic and environmental risk factors are identified in the development of leukemia. According to the Surveillance, Epidemiology, and End Results (SEER) database, there are 61,090 estimated new cases of leukemia in 2021, accounting for 3.2% of all new cancer cases, making leukemia the 10th most common cancer in the United States. This activity describes the evaluation and management of leukemia and reviews the role of the interprofessional team in improving care for patients with this condition. Objectives: Identify the epidemiology of leukemia. Review the appropriate evaluation of leukemia. Outline the management options available for leukemia. Describe interprofessional team strategies for improving care coordination and communication when treating patients with leukemia. Access free multiple choice questions on this topic.

The production of abnormal leukocytes defines leukemia as either a primary or secondary process. They can be classified as acute or chronic based on the rapidity of proliferation and myeloid or lymphoid based on the cell of origin. Predominant subtypes are acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), which involve the myeloid lineage; acute lymphoblastic leukemia (ALL); and chronic lymphocytic leukemia (CLL), which involve the lymphoid lineage. Other less common variants, such as mature B-cell and T-cell leukemias, and NK cell-related leukemias, to name a few, arise from mature white blood cells. However, with the advent of next-generation sequencing (NGS) and the identification of various biomarkers, the World Health Organization (WHO) classification was updated in 2016, introducing significant changes to the traditional classification of acute leukemias and myeloid neoplasms.[1] GLOBOCAN, a global observatory for cancer trends, showed a global incidence of 474,519 cases, with 67,784 in North America. The Age-Standardized Rates are around 11 per 100,000, with a mortality rate of approximately 3.2.[2] Many genetic risk factors have been identified, such as Klinefelter and Down syndromes, ataxia telangiectasia, Bloom syndrome, and telomeropathies such as Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome; germline mutations in RUNX1, CEBPA, to name a few. Viral infections associated with Epstein-Barr virus, human T-lymphotropic virus, ionizing radiation exposure, radiation therapy, environmental exposure with benzene, smoking history, history of chemotherapy with alkylating agents, and topoisomerase II agents have also been implicated in the development of acute leukemias. Symptoms are nonspecific and can include fever, fatigue, weight loss, bone pain, bruising, or bleeding. Definitive diagnoses often require bone marrow biopsy, the results of which help the hematologists and stem cell transplant physicians regarding the selection of treatment options ranging from chemotherapy to allogeneic stem cell transplantation. The prognosis varies depending on the leukemia subtype.

Many genetic risk factors have been identified, such as Klinefelter and Down syndromes, ataxia telangiectasia, Bloom syndrome, and telomeropathies such as Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome; germline mutations in RUNX1, CEBPA, to name a few. Viral infections associated with Epstein-Barr virus, human T-lymphotropic virus, ionizing radiation exposure, radiation therapy, environmental exposure with benzene, smoking history, history of chemotherapy with alkylating agents, and topoisomerase II agents have also been implicated in the development of acute leukemias. Symptoms are nonspecific and can include fever, fatigue, weight loss, bone pain, bruising, or bleeding. Definitive diagnoses often require bone marrow biopsy, the results of which help the hematologists and stem cell transplant physicians regarding the selection of treatment options ranging from chemotherapy to allogeneic stem cell transplantation. The prognosis varies depending on the leukemia subtype. Acute vs chronic myeloid leukemia: Blasts, which are immature and dysfunctional cells, normally make up 1% to 5% of marrow cells. Acute leukemias are characterized by greater than 20% blasts on peripheral blood smear or bone marrow, leading to a more rapid onset of symptoms. In contrast, chronic leukemia has less than 20% blasts with a relatively chronic onset of symptoms. The accelerated/blast phase is a transformation of chronic myeloid leukemia into an acute phase with a significantly higher degree of blasts.[1][3][4] As such, the 4 major subtypes of leukemia are: Acute lymphoblastic leukemia (ALL): ALL occurs in patients with the blastic transformation of B and T cells. It is the most common leukemia in the pediatric population, accounting for up to 80% of cases in this group vs 20% of cases in adults. Pediatric regimens predominantly inform treatment for adolescents and young adults, with better survival rates. Acute myelogenous leukemia (AML): AML is characterized by greater than 20% myeloid blasts and is the most common acute leukemia in adults. It is the most aggressive cancer with a variable prognosis depending on the molecular subtypes.

Acute lymphoblastic leukemia (ALL): ALL occurs in patients with the blastic transformation of B and T cells. It is the most common leukemia in the pediatric population, accounting for up to 80% of cases in this group vs 20% of cases in adults. Pediatric regimens predominantly inform treatment for adolescents and young adults, with better survival rates. Acute myelogenous leukemia (AML): AML is characterized by greater than 20% myeloid blasts and is the most common acute leukemia in adults. It is the most aggressive cancer with a variable prognosis depending on the molecular subtypes. Chronic lymphocytic leukemia (CLL): CLL occurs from the proliferation of monoclonal lymphoid cells. Most cases occur in people aged 60 to 70. CLL is considered an indolent disease, for the most part, meaning not all patients with a diagnosis need to start treatment until symptomatic from the disease. Chronic myelogenous leukemia (CML): CML typically arises from reciprocal translocation and fusion of BCR on chromosome 22 and ABL1 on chromosome 9, resulting in dysregulated tyrosine kinase on chromosome 22 called the Philadelphia (Ph) chromosome. This, in turn, causes a monoclonal population of dysfunctional granulocytes, predominantly neutrophils, basophils, and eosinophils.[1][3][5][6]

Multiple genetic and environmental risk factors are identified in the development of leukemia. Exposure to ionizing radiation is associated with an increased risk of multiple leukemia subtypes.[7][8] Exposure to benzene is a risk factor for leukemia in adults, particularly AML.[9] Previous exposure to chemotherapy, especially alkylating agents and topoisomerase II inhibitors, increases the risk for acute leukemia later in life.[7][8] A history of any hematologic malignancy is a risk factor for subsequently developing another subtype of leukemia.[10] Viral infections (eg, human T-cell leukemia virus and Epstein-Barr virus) are associated with subtypes of ALL.[11] Several genetic syndromes (eg, Down syndrome, Fanconi anemia, Bloom syndrome, Li-Fraumeni syndrome) are associated with an increased risk of AML and ALL.[12]

GLOBOCAN, which is a global observatory for cancer trends, showed a global incidence of 474,519 cases, with 67,784 in North America. The age-standardized rates are around 11 per 100,000, with a mortality rate of about 3.2. ALL and AML, which are important diseases in both childhood and adulthood, have bimodal age distributions, with CML and CLL mostly in the older age groups. According to the Surveillance, Epidemiology, and End Results (SEER) database, there were 61,090 estimated new leukemia cases in 2021, accounting for 3.2% of all new cancer cases, making leukemia the 10th most common cancer in the United States. Estimated deaths are about 23,660, which comprises 3.9% of all cancer deaths. Since 2006, the incidence of the disease has increased by an average of 0.6% per year, while mortality has decreased by an average of 1.5% per year.[6][7]

Leukemia arises from the malignant transformation of pluripotent hematopoietic stem cells (ie, those that can give rise to both myeloid and lymphoid precursors). Rarely, it can also involve a more committed stem cell with limited self-renewal capacity. In acute leukemias, these malignant cells are generally immature, poorly differentiated, abnormal leukocytes (blasts) that can either be lymphoblasts or myeloblasts. These blasts can undergo clonal expansion and proliferation, leading to replacement and interference with the development and function of normal blood cells, thereby causing clinical symptoms. Acute Leukemia In ALL, chromosomal translocations or abnormal chromosome numbers can cause mutations in precursor lymphoid cells, resulting in lymphoblasts. Common mutations include t(12;21) and t(9;22). In AML, chromosomal translocations, rearrangements, and gains or losses of chromosomes can lead to mutations and the abnormal production of myeloblasts. One important translocation is t(15;17), which results in the fusion of the retinoic acid receptor alpha (RARA) gene with the promyelocytic leukemia (PML) gene. This leads to the development of acute promyelocytic leukemia, which can present with hallmarks of disseminated intravascular coagulation and need emergent treatment with all-trans retinoic acid. Chronic Leukemia Chromosomal abnormalities in hematopoietic stem cells that are precursors to leucocytes are the most common cause of chronic leukemia. Examples of abnormalities are deletions, translocations, or extra chromosomes. In CML, mutations mainly affect granulocytes (most commonly the t(9;22) translocation), and in CLL, they primarily affect lymphocytes (especially B lymphocytes). Unlike acute leukemias, cells in chronic leukemias are partially mature. These partially mature cells do not function effectively and divide too quickly. They accumulate in peripheral blood and lymphoid organs, leading to anemia, thrombocytopenia, and leukopenia.

Acute Leukemia In acute leukemia, the peripheral blood or bone marrow is characterized by more than 20% blasts. However, regardless of the blast percentage, patients with t(8;21)(q22;q22), RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11 or t(15;17)(q24.1;q21.1), PML-RARA, are considered and treated as acute leukemia. There is usually increased cellularity on bone marrow biopsy, with blasts packed into the marrow and a variable number of granulocytic or monocytic cells and erythroid precursors. Traditional markers included in the evaluation are CD7, CD11b, CD13, CD14, CD15, CD16, CD33, CD34, CD45, CD56, CD117, HLA-DR. Also, either a peripheral smear or a bone marrow aspirate is sent for a mutation panel of multiple genes with therapeutic and prognostic implications, such as ASXL1, CEBPA, DNMT3A, FLT3, IDH1, IDH2, NPM1, RUNX1, and TP53, to name a few. There is also increased bone marrow cellularity in ALL, composed of B and T lymphoblasts (with small nucleoli, dispersed chromatin, cleaved and irregular nuclei with undetectable cytoplasm). Common T-cell lymphoid immunostains include TdT, CD2, CD3, CD5, and CD7. Common B-cell lymphoid immunostains include HLA-DR, CD10, CD19, CD22, CD79a, PAX5, and CD20. There should be no myeloid markers, such as myeloperoxidase (MPO), to confirm a pure lymphoid lineage. Mixed phenotype acute leukemia (MPAL) has both myeloid and lymphoid markers, but is a rare entity. Cytogenetic evaluation for Ph chromosome status and Ph-like translocations is essential, as newer therapeutic agents are now incorporated into treatment algorithms.[13] Chronic Leukemia The white blood cell count in chronic leukemia is often elevated, with a smear suggestive of significant left shift/granulocyte predominance. Such a picture is commonly seen during the acute illness phase, but if it persists on repeat labs, CML should be evaluated. In CML, the translocation t(9;22) can be diagnosed by fluorescence in situ hybridization (FISH) on peripheral blood. Bone marrow biopsy is not necessary for diagnosis, but if done, it usually shows 100% cellular marrow with increased granulocyte precursors, basophils, eosinophils, and occasional monocytes.

The white blood cell count in chronic leukemia is often elevated, with a smear suggestive of significant left shift/granulocyte predominance. Such a picture is commonly seen during the acute illness phase, but if it persists on repeat labs, CML should be evaluated. In CML, the translocation t(9;22) can be diagnosed by fluorescence in situ hybridization (FISH) on peripheral blood. Bone marrow biopsy is not necessary for diagnosis, but if done, it usually shows 100% cellular marrow with increased granulocyte precursors, basophils, eosinophils, and occasional monocytes. In CLL, the white cell count is elevated, with mostly CD5+ and CD23+ B-lymphocytes. The clonal lymphocyte population has to be greater than 5,000/mcL for diagnosis. If the clonal lymphocyte population is less than 5,000/mcL, the entity is termed monoclonal B cell lymphocytosis of undetermined significance. Flow cytometry is often diagnostic. Patients would need evaluation for del(17p) and TP53 mutation status, immunoglobulin heavy chain variable region (IGHV) gene mutation status, del(11q), del(13q), and trisomy 12, to help select appropriate treatment regimens.[14]

Acute Leukemia Acute leukemia tends to present non-specifically, although the most common presenting features include fever, lethargy, and bleeding. Hepatosplenomegaly, lymphadenopathy, and musculoskeletal symptoms (especially involving the spine and long bones) can also be clues to the diagnosis. Adults may also have more prominent anemia-related symptoms, such as shortness of breath, or symptoms related to thrombocytopenia, such as excessive bruising or increased bleeding tendency. Patients with acute promyelocytic leukemia (APL), which is associated with disseminated intravascular coagulation-type symptoms, can present with mucosal bleeding, including gum bleeds, nosebleeds, or menorrhagia. Chronic Leukemia Chronic leukemia subtypes occur almost exclusively in adults. Many patients are asymptomatic at the time of diagnosis, identified only incidentally after marked leukocytosis is discovered on a complete blood count (CBC) performed for another reason. Hepatosplenomegaly and lymphadenopathy can be appreciated in some cases, while bleeding and bruising are less common, presenting features relative to acute leukemia subtypes.[15]

The workup of leukemia is very involved, and multiple tests are needed to confirm a diagnosis and, subsequently, to stage the disease. Helpful initial studies include a CBC, comprehensive metabolic panel, liver function tests (LFT), and coagulation panel, which are often followed by a peripheral blood smear evaluation and a bone marrow biopsy and aspiration. On rare occasions, leukemia can be diagnosed on histology alone. For example, AML is characterized by the presence of Auer rods (red-staining, needle-like bodies seen in the cytoplasm of myeloblasts) on a peripheral smear. In most other cases, more detailed analyses using flow cytometry, cytogenetics, and FISH are required to distinguish subtypes.[16] A bone marrow aspiration and biopsy are often required for the diagnosis of acute leukemias. For chronic leukemias, peripheral blood evaluation is often enough, and an invasive bone marrow biopsy may not be needed. For example, CML can be diagnosed by detecting the BCR-ABL fusion protein in peripheral blood using FISH analysis. CLL can be diagnosed by looking for a monoclonal B-cell population through peripheral blood flow cytometry.

Patients with leukemia should be referred to a hematologist-oncologist to initiate treatment. Therapy varies significantly based on the leukemia subtype and patient factors (eg, age, comorbid conditions). Acute leukemias are treated predominantly as inpatients, requiring significant support, frequent vital sign monitoring, and assessment for opportunistic infections and electrolyte imbalances. The predominant challenge at the time of diagnosis of acute myeloid leukemia is to identify the possibility of APL, which has a significantly different treatment compared to the rest of AML. APL: APL patients typically present with bleeding diathesis with increased coagulation parameters (elevated PT, aPTT) and low fibrinogen. Peripheral smear shows a predominance of myeloid blasts with Auer rods. It is important to start the treatment with ATRA (all-trans-retinoic acid) when APL is suspected rather than awaiting confirmatory tests with FISH. ATRA advances arrested promyeloblasts toward mature granulocytes, which can lead to differentiation syndrome.[17] Differentiation syndrome is seen during 48 hours of ATRA initiation to even 3 weeks from starting therapy for APL. Patients have a fever, respiratory distress with acute pulmonary infiltration on imaging, and capillary leak resulting in edema. It can mimic sepsis, resulting in delaying the treatment with dexamethasone. The commonly accepted starting dosage is 10mg every 12 hours till improvement in symptoms and counts.[18] Other significant complications with ATRA include raised intracranial pressure, leading to headaches and significant vision changes from papilledema. Specific treatment for APL depends on whether the patient is at low or intermediate risk (also known as standard risk) with a WBC count <10,000/mL or at high risk with a WBC count >10,000/mL. Low or intermediate-risk APL is further differentiated by platelets above or below 40,000/mcL. Standard-risk APL: Patients respond well to ATRA and arsenic trioxide (ATO), with fewer complications during induction and recovery, without requiring an allogeneic stem cell transplant (SCT). During ATO use, patients need to be closely monitored for electrolyte changes and for electrocardiogram QTc prolongation (Framingham formula).[19]

Standard-risk APL: Patients respond well to ATRA and arsenic trioxide (ATO), with fewer complications during induction and recovery, without requiring an allogeneic stem cell transplant (SCT). During ATO use, patients need to be closely monitored for electrolyte changes and for electrocardiogram QTc prolongation (Framingham formula).[19] High-risk APL: In addition to ATRA + ATO, high-risk patients achieve better responses with the addition of idarubicin.[20] Recent studies have included CD33-targeted drug conjugate, gemtuzumab ozogamicin (GO), during the induction therapy combined with ATRA + ATO.[21] APL patients have better overall survival and prognosis than other types of AML without needing a transplant. AML: Standard therapy for AML is well known as the '7+3' regimen, which includes a 7-day course of cytarabine continuous infusion with a 3-day course of an anthracycline (either daunorubicin or idarubicin). With the advent of cytogenetics and NGS testing, patients are now being risk-stratified based on molecular markers, with prognostic and therapeutic implications.[22] The outline of therapy based on the risk status per ELN (European LeukemiaNet) is as follows Table Standard 7+3 regimen with/without GO.[23] This chemo regimen can be attempted in patients > 60 years old if they have good tolerability as determined by performance status. ALL ALL is divided into B or T lymphocyte variants based on the lymphoblast origin and the presence of >20% lymphoblasts in peripheral smear or BM. The presence or absence of the Ph chromosome is the most important molecular marker leading to therapeutic implications in treating ALL. Table A combination of chemotherapy with an oral tyrosine kinase inhibitor (TKI) is preferred for 2nd-generation and beyond agents, such as dasatinib, ponatinib, bosutinib, nilotinib, and imatinib. Not all the TKI combinations have data with chemotherapy agents, (more...) The overall outcome depends upon the patient's response to induction therapy and the presence or absence of MRD (minimal residual disease) needing further therapies and BMT.

A combination of chemotherapy with an oral tyrosine kinase inhibitor (TKI) is preferred for 2nd-generation and beyond agents, such as dasatinib, ponatinib, bosutinib, nilotinib, and imatinib. Not all the TKI combinations have data with chemotherapy agents, (more...) The overall outcome depends upon the patient's response to induction therapy and the presence or absence of MRD (minimal residual disease) needing further therapies and BMT. CML: CML is 1 of the 1st cancers revolutionized by utilizing targeted therapy with Ph chromosome targeting TKIs. Patients have a significant response to TKIs, negating the need for acute chemotherapy unless they are in an accelerated phase/blast crisis. A patient's risk can be assessed based on multiple available calculators, such as the Sokal score, EUTOS Score, and EUTOS long-term survival score (ELTS).[36][37][38] For patients with high-risk disease, second-generation (nilotinib, dasatinib, and bosutinib) TKIs are used as 1st-line therapy to achieve therapy milestones more quickly with deeper responses.[39] For low and intermediate-risk patients, imatinib can be initiated as 1st-line therapy. However, there is no significant difference in overall survival by TKI generation. Major milestones after initiation of TKI include: At 3 months: BCR-ABL1 [International Scale (IS)] at ≤10 percent and/or ≤35% Ph-positive metaphase cells At 6 months: BCR-ABL1 (IS) at ≤1 percent or/and 0 % Ph-positive metaphase cells At 1 year: BCR-ABL1 (IS) ≤0.1 percent Patients need to be monitored for resistance mutations, predominantly the T315I mutation, for which ponatinib, asciminib, and omacetaxine are approved.[40][41] Patients might continue to develop resistance to multiple TKIs for whom SCT can be attempted. CLL: CLL runs its course in a more indolent fashion than all the other leukemic subtypes, with the patient's lifespan minimally impacted by the disease. Patients do not benefit from early treatment unless they meet the criteria for therapy. Patients with rapid lymphocyte doubling time, worsening cytopenias, increasing spleen size causing abdominal discomfort, and significant B symptoms (fatigue, night sweats, and weight loss) benefit from treatment. The most important determinants in treating CLL are the IGVH mutation status and the presence of del17p and TP53 mutations. t(11:14) is often obtained to rule out mantle cell lymphoma.

CLL: CLL runs its course in a more indolent fashion than all the other leukemic subtypes, with the patient's lifespan minimally impacted by the disease. Patients do not benefit from early treatment unless they meet the criteria for therapy. Patients with rapid lymphocyte doubling time, worsening cytopenias, increasing spleen size causing abdominal discomfort, and significant B symptoms (fatigue, night sweats, and weight loss) benefit from treatment. The most important determinants in treating CLL are the IGVH mutation status and the presence of del17p and TP53 mutations. t(11:14) is often obtained to rule out mantle cell lymphoma. For patients with IGVH mutation who have a relatively good prognosis, chemotherapy with FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) can be attempted as patients would be able to achieve prolonged disease-free survival for over 10 years.[42][43] For high-risk patients with del17p/TP53 mutation, targeted therapy with venetoclax (BCL-2 inhibitor) or Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib) is beneficial, either as a single agent or in combination with rituximab or obinutuzumab.[44][45][46][47] Older patients with comorbidities tolerate BTK inhibitors better. Rarely do patients with CLL/SLL who have a dormant course present with acute aggressive lymphadenopathy. They need an urgent lymph node or bone marrow biopsy to rule out Richter transformation into aggressive diffuse large B-cell lymphoma and, rarely, Hodgkin lymphoma or T-cell lymphomas.

The differential diagnosis is broad because leukemia is a broad diagnosis with non-specific symptoms. One must rule out infection, drug effects, vitamin/micronutrient deficiencies, and other myelodysplastic disorders that can cause abnormalities in blood cell lines. Consider the following when seeing abnormalities in the blood count: B12 and folate deficiencies Copper deficiencies Viral infections (eg, HIV, cytomegalovirus, Epstein-Barr virus) Drugs (chemotherapeutic agents, valproic acid, ganciclovir, mycophenolate mofetil) Autoimmune conditions (eg, systemic lupus erythematosus)

Long-term survival with leukemia varies tremendously based on leukemia subtype, cytogenetic and molecular findings, patient age, and comorbid conditions. Broadly, leukemia's 5-year cancer survival rate increased from 33% in 1975 to 59% in 2005.[6]

Tumor Lysis Syndrome (TLS) TLS is a complication of chemotherapy that can result when tumor cells die quickly. The widespread cellular destruction releases intracellular contents into the bloodstream, overwhelming the kidneys and resulting in dangerously high serum levels of potassium, phosphorus, and uric acid.[48] Patients need aggressive hydration, frequent lab monitoring, and management of hyperuricemia with allopurinol and rasburicase. Hyperkalemia and hypocalcemia can lead to significant cardiac toxicity requiring urgent correction. Disseminated Intravascular Coagulation (DIC) DIC is a complication of leukemia itself in which the proteins that control the blood clotting process become dysfunctional, leading to both thrombosis and hemorrhage. DIC is often associated with acute promyelocytic leukemia, but can be seen in other subtypes of leukemia as well.[16] Frequent lab monitoring with active replacement of fibrinogen with cryoprecipitate is vital to the patient's survival. Infection Immunosuppression from chemotherapy, stem cell transplantation, or leukemia itself increases the risk of dangerous infections. Fever with neutropenia in an immunosuppressed patient should prompt an immediate evaluation for the source of infection and the initiation of broad-spectrum antibiotic therapy.[49] Cancer Survivors of leukemia are at an increased risk of subsequent cancers. For example, the Childhood Cancer Survivor Study demonstrated that the 30-year cumulative incidence of any cancer after leukemia was 5.6%; the median time to occurrence of the subsequent cancer was 9 years. The most common second neoplasms in childhood leukemia survivors are different subtypes of leukemia or lymphoma.[10]

Leukemia is the production of abnormal white blood cells from bone marrow and lymphatic tissues. Excess production of these white blood cells disrupts the production of normal blood cells, which are essential for fighting infections, carrying oxygen, and helping blood clot. Such abnormal cell production can be fast, making it acute leukemia or a relatively slower process leading to chronic leukemia. Common symptoms include recurrent infections, weight loss, fatigue, fevers, abdominal pain, and bleeding. Multiple types of leukemias are present, and they require evaluation by a hematologist for further guidance on treatment.

Acute and chronic leukemias are heterogeneous hematologic diseases with complex diagnostic and therapeutic implications requiring an interprofessional healthcare team. The involvement of healthcare professionals from across specialties and disciplines - clinicians, nurses, specialists (especially hematologists and oncologists), pharmacists, nutritionists, etc - is needed to achieve effective management, mitigate adverse events, and ensure their quality of life. The patient's initial encounter is often with their family clinician, who runs initial bloodwork and other tests, but specialist input is an absolute necessity if there are any indications that leukemia is the diagnosis. Specialists primarily guide the therapy regimen, but nurses play a pivotal role in evaluating patients, coordinating activities among specialists, and providing patient counseling. A specialized oncology pharmacist is a valuable asset to the team. Their consultation can help guide chemotherapy, appropriate dosing, medication reconciliation, and medication counseling for patients, especially regarding adverse events. All interprofessional team members must maintain meticulous records on all interactions and interventions with the patient; this is part of communicating all patient data to the rest of the team. Everyone involved in care must keep other team members informed of any changes in the patient's condition as appropriate and include the patient in all care decisions, answering questions and offering counsel. Patient-centered communication and shared decision-making are integral to successful patient outcomes in the interprofessional team model.